FDA Approval Alert: The Need-to-Know | Nivolumab-Based Regimens for Esophageal Squamous Cell Carcinoma

In May 2022, nivolumab plus chemotherapy and nivolumab plus ipilimumab was approved by the FDA as a treatment for patients with unresectable advanced or metastatic esophageal squamous cell carcinoma regardless of PD-L1 expression.

Jaffer A. Ajani, MD, Discusses the Approval of Nivolumab Combinations in Esophageal Squamous Cell Carcinoma
Jaffer A. Ajani, MD, Discusses the Approval of Nivolumab Combinations in Esophageal Squamous Cell Carcinoma
Video
May 31, 2022 8:00 PM
Jaffer A. Ajani, MD, spoke about the recent approvals of nivolumab plus ipilimumab and nivolumab plus chemotherapy for patients with esophageal squamous cell carcinoma.
FDA Approves Nivolumab/Chemo and Nivolumab/Ipilimumab for Unresectable Advanced ESCC
FDA Approves Nivolumab/Chemo and Nivolumab/Ipilimumab for Unresectable Advanced ESCC
Article
May 31, 2022 4:00 PM
The FDA has granted approval to nivolumab plus ipilimumab and nivolumab plus chemotherapy for patients with unresectable advanced or metastatic esophageal squamous cell carcinoma.